Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial

Calcineurin inhibitors (CNI e.g. tacrolimus) reduce short-term kidney transplant failure, but chronic nephrotoxicity may contribute to late transplant loss. Elective conversion to inhibitors of the mammalian target of rapamycin pathway (mTOR e.g. sirolimus) might avoid long-term CNI renal damage an...

Full description

Bibliographic Details
Main Authors: Haynes, R, Blackwell, L, Staplin, N, Herrington, W, Emberson, J, Judge, P, Storey, B, Landray, M, Baigent, C, Friend, P
Format: Journal article
Published: Wiley 2018

Similar Items

Similar Items